Clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication Significant cardiovascular disease (New York Heart Association Class II or greater), myocardial infarction within the 6 months prior to study entry, unstable angina, or cerebral vascular accident / stroke (< 6 months prior to enrollment), or serious uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected QT interval [QTc] prolongation of > 470ms and/or prior diagnosis of congenital long QT syndrome. Uncontrolled or significant cardiovascular disease, including any of the following:\r\n* Symptomatic congestive heart failure (>= New York Heart Association Classification class II)\r\n* Cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), or unstable angina\r\n* Uncontrolled hypertension or uncontrolled cardiac arrhythmia PHASE II EXCLUSION CRITERIA: Uncontrolled or significant cardiovascular disease, including any of the following:\r\n* Symptomatic congestive heart failure (>= New York Heart Association Classification class II)\r\n* Cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), or unstable angina\r\n* Uncontrolled hypertension or uncontrolled cardiac arrhythmia Within 6 months prior to study drug administration, clinically significant cardiovascular/cerebrovascular disease defined as follows: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association classification class >= II), bleeding or pulmonary embolism or cardiac arrhythmias that was severe enough to cause hemodynamic compromise Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke < 6 months prior to enrollment, myocardial infarction < 6 months prior to enrollment, unstable angina, congestive heart failure (>= New York Heart Association [NYHA] III) or serious cardiac arrhythmia requiring medication Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association classification class > II), or serious cardiac arrhythmia. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication; patients with stable rate-controlled atrial fibrillation will be allowed to participate Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification class >= II), or serious cardiac arrhythmia Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication Clinically significant cardiovascular/ cerebrovascular disease as follows: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification class > II), or serious cardiac arrhythmia. Clinically significant (i.e., active) cardiovascular disease: acute cerebral vascular accident/stroke (< 6 months prior to enrollment) excluding transient ischemic attack (TIA), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (? New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Uncontrolled intercurrent illness including, but not limited to, clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), congestive heart failure (>= New York Heart Association [NYHA] class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication Clinically significant cardiovascular / cerebrovascular disease as follows: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association classification class >= II), serious cardiac arrhythmia, clinically significant bleeding or clinically significant pulmonary embolism Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (? New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant cardiovascular disease including cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), congestive heart failure with New York Heart Association (NYHA) class II or greater or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association [NYHA] class >= II), or serious uncontrolled cardiac arrhythmia Clinically significant (active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study enrollment; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication. Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class >= II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months prior to study entry; unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring medication. Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, clinically significant cardiovascular disease including: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements; ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months before enrollment), myocardial infarction (<6 months before enrollment), unstable angina, congestive heart failure (New York Heart Association class ?II), or serious uncontrolled cardiac arrhythmia requiring medication. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association classification class II), or serious cardiac arrhythmia requiring medication Patients with a history of stroke or intracranial hemorrhage within 6 months prior to registration are not eligible History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment No active intracranial metastases History of stroke/intracranial hemorrhage =< 6 months prior to registration History of stroke or intracranial hemorrhage within 6 months prior to randomization History of stroke or intracranial hemorrhage within 6 months of first dose Intracranial hemorrhage grade > 1 not attributable to recent neurosurgery History of stroke or intracranial hemorrhage within 6 months prior to enrollment Any history of symptomatic intracranial hemorrhage. Patients should not have a stroke or intracranial hemorrhage within last 6 months Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registration History of stroke/intracranial hemorrhage =< 6 months prior to registration History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months of the first dose of study drug History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment Evidence of acute intracranial / intra-tumoral hemorrhage, except for participants with stable grade 1 hemorrhage. History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to randomization Intracranial hemorrhage except for tumor associated micro hemorrhage. History of stroke or intracranial hemorrhage within 6 months prior to study entry History of intracranial hemorrhage (either by clinical history or neuroimaging) History of stroke or intracranial hemorrhage within 6 months of screening No history of intracranial hemorrhage Relapsed/refractory MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent Newly diagnosed MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent Evidence of recent (less than 2 weeks) intracranial hemorrhage. Have evidence of significant (ie, symptomatic) intracranial hemorrhage. History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrolment History of stroke or intracranial hemorrhage within 3 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to signing the consent. History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months before randomization. History of stroke or intracranial hemorrhage within 6 months before randomization. history of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. History of stroke or intracranial hemorrhage within 6 months prior to enrollment No stroke or intracranial hemorrhage within the last 6 months History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment. History of stroke or intracranial hemorrhage within 6 months prior to enrollment Patient has history of stroke or intracranial hemorrhage =< 6 months from starting study drugs History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to study entry Active intracranial hemorrhage History of stroke or intracranial hemorrhage within 6 months prior to the first dose of ibrutinib History of stroke or intracranial hemorrhage within 6 months prior to enrollment. History of stroke or intracranial hemorrhage within 12 months prior to enrollment. Subjects with a history of stroke or intracranial hemorrhage within 6 months prior to enrollment are not eligible History of stroke or intracranial hemorrhage within 6 months prior to randomization History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to random assignment History of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage. History of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular disease History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months of screening would be exclusion for ibrutinib therapy but idelalisib would be an option History of stroke or intracranial hemorrhage within 6 months prior to registration History of stroke or intracranial hemorrhage within 6 months prior to enrollment Patients with a history of known stroke or intracranial hemorrhage within 6 months prior to study treatment are excluded History of stroke or intracranial hemorrhage within 6 months prior to enrollment. History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment Patients with a history of intracranial hemorrhage are not eligible. History of stroke or intracranial hemorrhage =< 6 months prior to registration History of stroke or intracranial hemorrhage within 6 months prior to treatment Evidence of significant intracranial hemorrhage History of stroke or intracranial hemorrhage within 6 months of enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment History of stroke or intracranial hemorrhage within 6 months prior to enrollment Diagnosis of intracranial hemorrhage within the past 3 months, including intratumoral hemorrhage into brain metastases from a systemic cancer Any history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure) EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or intracranial hemorrhage within 6 months prior to screening Patients must not have evidence of significant intracranial hemorrhage History of stroke or intracranial hemorrhage within 6 months prior to enrollment No hemorrhage after treatment. History of stroke or intracranial hemorrhage within 6 months of first dose No history of any prior stroke (hemorrhagic or ischemic) History of stroke within 6 months. Stroke. Known history of stroke or cerebrovascular accident within 6 months before enrollment. Any history of hemorrhagic stroke History or evidence of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) not associated with any antitumor surgery within 6 months before enrolment Stroke, serious cardiac arrhythmia within the 6 months prior to study drug administration History of ischemic stroke within 6 months prior to enrollment. History of hemorrhagic or ischemic stroke within the last 6 months Previous stroke < 12 months History of stroke within the last 5-years History of stroke or cerebral hemorrhage within 2 months History of central nervous system bleeding as defined by stroke or intraocular bleed within 6 months of enrollment. History of stroke or cerebral hemorrhage within 6 months History of stroke or cerebral hemorrhage within 2 month Patient with stroke in the last 3 months History of stroke within 6 months History of stroke within 6 months History (within the last 3 months) or presence of stroke/cerebrovascular accident TIA or stroke in the last 1 month. TIA or stroke in the last 1 month History of stroke within six months History of cerebral vascular accident or stroke within the previous 2 years Known history of stroke or cerebrovascular accident within 6 months prior to enrollment History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months. Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months. History of stroke or cerebral hemorrhage within 6 months Known history of stroke or cerebrovascular accident within 6 months prior to enrollment Known history of stroke or cerebrovascular accident within 6 months prior to enrollment History of stroke or cerebral hemorrhage within 2 months Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug PART B: Any history of myocardial infarction or embolic/occlusive cerebro-vascular accident (stroke) History of stroke within 6 months prior to study registration History of stroke within 6 months of registration History of stroke within 6 months prior to day 1 History of stroke Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of protocol therapy. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug. 5. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug. Known history of stroke or cerebrovascular accident within 6 months. History of stroke within 6 months History of hemorrhagic or ischemic stroke within 6 months prior to first dose of mirvetuximab soravtansine Hemorrhagic, embolic, or thrombotic stroke within 6 months of scheduled dosing day 1; History of stroke within 6 months prior to study enrollment. History of a prior symptomatic stroke, dementia, or other significant central neurologic condition (i.e. multiple sclerosis) History of stroke within six months History (within the last 6 months) or presence of stroke/cerebrovascular accident History of stroke or cerebral hemorrhage within 2 months EXCLUSION - STUDY 1: Stroke Stroke within the past 2 years History of stroke No history of hemorrhagic stroke stroke (within the last 6 month) History of bleeding disorder or hemorrhagic stroke Stroke in the last six months History of severe brain-injury or stroke. History of bleeding disorder or hemorrhagic stroke History of cerebrovascular accident (stroke) Stroke or TIA within 12 last months History of stroke with the past year History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months Subjects with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within 6 months of the first date of treatment on this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage. Patients with history or evidence upon physical examination of central nervous system (CNS) disease; seizures not controlled with standard medical therapy; any brain metastases; or history of cerebral vascular accident (CVA), transient ischemic attack (TIA), or subarachnoid hemorrhage within 6 months of the first date of treatment on this study; patients diagnosed with primary brain tumors within the last three years are also excluded Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study are ineligible History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or a history of stroke within 5 years of the first date of treatment on this study Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first dose of study drug. History or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, any brain metastases and/or epidural disease, or history of cerebrovascular accident (cerebrovascular accident [CVA], stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study. Subjects with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or, within six months prior to Day 1 of this study, history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage. Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study. Any known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage Subjects with history of evidence upon physical examination of central nervous system (CNS) disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of study entry Subjects with a history of evidence upon physical examination of central nervous system (CNS) disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within six months of study entry